> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-181/
- Published: 2018-05-28T12:00:00.000Z
- Updated: 2026-09-15T00:08:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141554

[**Guide on Anthrax Prevention Drugs**](https://www.fdaweb.com/guide-on-anthrax-prevention-drugs/)  
*Federal Register* notice: FDA makes available a guidance entitled ‘‘Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax.’’ 05/24/2018

[**Comments Sought on Study Design for Heartworm Drugs**](https://www.fdaweb.com/comments-sought-on-study-design-for-heartworm-drugs/)  
*Federal Register* notice: FDA seeks comments as it evaluates current thinking about the design of studies intended to generate data to support investigational new animal drugs intended for preventing heartworm disease in dogs. 05/24/2018

[**Info Collection Extension for PDMA Policies, Requirements**](https://www.fdaweb.com/info-collection-extension-for-pdma-policies-requirements/)  
*Federal Register* notice: FDA submits to OMB for approval an information collection extension for “Prescription Drug Marketing Act of 1987 — Administrative Procedures, Policies, and Requirements” (OMB Control Number 0910–0435). 05/24/2018

[**Guide on OTC Sunscreen Enforcement Policy**](https://www.fdaweb.com/guide-on-otc-sunscreen-enforcement-policy/)  
*Federal Register* notice: FDA makes available a guidance entitled “Enforcement Policy — OTC Sunscreen Drug Products Marketed Without an Approved Application.” 05/23/2018

[**Guide on OTC Maximal Usage Drug Trials**](https://www.fdaweb.com/guide-on-otc-maximal-usage-drug-trials/)  
*Federal Register* notice: FDA makes available a draft guidance for industry entitled “Maximal Usage Trials for Topical Active Ingredients Being Considered for Inclusion in an Over-the-Counter Monograph: Study Elements and Considerations.” 05/23/2018

[**Panel to Review Opioid NDA with Abuse-deterrent Properties**](https://www.fdaweb.com/panel-to-review-opioid-nda-with-abuse-deterrent-properties/)  
*Federal Register* notice: FDA announces a 6/26 joint advisory committee meeting to review a Pain Therapeutics NDA for a proposed abuse-deterrent oxycodone extended-release capsule. 05/23/2018

[**Guidance on OTC Sunscreen Product Enforcement Policy**](https://www.fdaweb.com/guidance-on-otc-sunscreen-product-enforcement-policy/)  
*Federal Register* notice: FDA posts a guidance on “Enforcement Policy — OTC Sunscreen Drug Products Marketed Without an Approved Application.” 05/22/2018

[**Comments Sought on ANDA Controlled Correspondence**](https://www.fdaweb.com/comments-sought-on-anda-controlled-correspondence/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for its “Guidance for Industry: Controlled Correspondence Related to Generic Drug Development.” 5/22/2018

[**Comments Sought on pH-dependent Drug-Drug Interactions**](https://www.fdaweb.com/comments-sought-on-ph-dependent-drug-drug-interactions/)  
*Federal Register* notice: FDA establishes a public docket to assist with developing a policy or guidance document on assessing pH-dependent drug-drug interactions. 05/22/2018

[**Guide on Bioanalytical Method Validation**](https://www.fdaweb.com/guide-on-bioanalytical-method-validation-3/)  
*Federal Register* notice: FDA makes available a guidance entitled “Bioanalytical Method Validation.”05/22/2018